Original articleSeven-versus 14-day course of antibiotics for the treatment of bloodstream infections by Enterobacterales: a randomized, controlled trial
Introduction
The duration of antimicrobial treatment for bloodstream infections caused by members of the Enterobacterales (eBSIs) has traditionally been supported by experts' opinions. Different scientific societies propose treating catheter-related eBSI for a variable duration of between 7 and 14 days [1,2], and no recommendations exist for other sources. The current scenario of rapidly spreading bacterial resistance at a global level mandates initiatives to stop this threat [3], and shortening the duration of antibiotic treatments is probably one of the most effective measures to avoid the emergence of resistance [4]. Producing good-quality evidence to support the effectiveness of shorter courses of antibiotics should be a priority, especially for common clinical situations. Hitherto, two non-inferiority trials have been published showing similar outcomes in patients receiving 7 versus 14 days of antibiotic treatment for bacteraemia caused by Gram-negative bacilli [5,6]. However, the question remains open for specific subgroups of patients—such as immunocompromised patients or males with urinary tract infections—for whom short courses may not be as effective as longer ones [7,8]. Thus, additional evidence would be still useful to allow balancing more accurately the theoretical benefits of shortening antibiotic treatments (i.e. reduced risk of adverse reactions or superinfections) versus the potential for impaired effectiveness in some patients.
The aim of the present trial was to prove that a 7-day course of antibiotics will allow a reduction in patients' exposure to antibiotics while achieving clinical outcomes similar to those of the traditional 14-day schemes for treating patients with eBSI.
Section snippets
Design
This was an open-label, multicentre, randomized, controlled, phase IV trial. Five Spanish hospitals participated in the trial between September 2014 and September 2016.
Participants
Adults over the age of 18 years with a diagnosis of eBSI were recruited. Hospitalized patients and outpatients were eligible. Exclusion criteria were: (a) pregnancy, (b) eBSI with a non-controlled source and no expectation of being controlled in the subsequent 24 h, (c) patients undergoing chemotherapy with neutropenia
Baseline characteristics
Among 248 randomized patients, 231 (93.1%) were assessed for the primary and secondary outcomes, with 17 patients lost to follow-up (nine in the short-treatment arm and eight in the prolonged-treatment arm) (Fig. 2, Supplementary Material Files 3 and 4). Baseline characteristics were in general well balanced between groups, except for respiratory source and chronic kidney disease, which were more frequent in the control group (Table 1).
Outcomes
The median length of antibiotic treatment at the end of the
Discussion
The results of this trial suggest that 7-day courses of antibiotics may be the preferential strategy for treating bacteraemic infections caused by Enterobacteriaceae, whenever an adequate control of the source is provided.
In order to ensure the safety of the intervention, some secondary endpoints were settled. Compared to 14-day treatments, non-inferiority was shown for clinical cure and relapse of eBSI. The predefined non-inferiority margin was barely unmet for the relapse of fever. It should
Author contributions
JMC and JM conceived and designed the study. CRF and BS supervised and coordinated the accomplishment of legal procedures required for the trial as well as its monitoring. JM, JPS, MH, ELJ, CN, EL, RAM, AIAG, AC, BGG, JEC, IMG and AVM recruited and performed the clinical follow-up of patients. CR and CI recorded data in the trial database. EM performed the statistical analysis. JM, JMC, JP, JMR, JEC, JT and JRB collaborated in the achievement of the public funds and provided the team with the
Transparency declaration
LELC declares consulting fees from Novartis and MSD, honoraria for lectures from Correvio, ViiV and Gilead, and participation on the advisory board for Angelini. AC declares honoraria for lectures from Pfizer and Shionogu. The remaining authors declare no conflicts of interests. The SHORTEN trial is a non-commercial, investigator-driven clinical trial supported by a grant from the Regional Ministry of Health of Andalusia (PI-0161/2013) and by Plan Nacional de I+D+i and Instituto de Salud Carlos
Acknowledgements
This work received technical support from the Spanish Network of Research in Infectious Diseases (REIPI) and the Spanish Clinical Research Network (SCReN) of the Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Spanish Government (PT13/0002/0010). The REIPI collaborated in the provision of human resources required for the trial tasks, and also provided the platform for the electronic case report form. We also acknowledge the endless availability of Alejandro
References (17)
- et al.
2016 Expert consensus document on prevention, diagnosis and treatment of short-term peripheral venous catheter-related infections in adults
Cir Cardiovasc
(2016) - et al.
Treatment duration for Escherichia coli bloodstream infection and outcomes: retrospective single-centre study
Clin Microbiol Infect
(2018) - et al.
Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial
Lancet Haematol
(2017) - et al.
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation
J Chronic Dis
(1987) - et al.
Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America
Clin Infect Dis
(2009) Antimicrobial resistance strategies and action plans
(2016)- et al.
Suppression of emergence of resistance in pathogenic bacteria: keeping our powder dry, Part 1
Antimicrob Agents Chemother
(2015) - et al.
Seven versus fourteen days of antibiotic therapy for uncomplicated Gram-negative bacteremia: a non-inferiority randomized controlled trial
Clin Infect Dis
(2019)
Cited by (57)
Early transition to oral therapy in gram-negative bloodstream infections: what is the next step?
2024, Clinical Microbiology and InfectionOral antibiotic step-down therapy for nonstaphylococcal gram-positive bloodstream infections
2023, Diagnostic Microbiology and Infectious DiseaseWhich trial do we need? Highly bioavailable oral β-lactams versus quinolones or trimethoprim-sulfamethoxazole for gram-negative bacteraemia
2023, Clinical Microbiology and InfectionUnlocking the DOOR—how to design, apply, analyse, and interpret desirability of outcome ranking endpoints in infectious diseases clinical trials
2023, Clinical Microbiology and InfectionDuration of antibiotic treatment and timing of oral switching for bloodstream infections: a survey on the practices of infectious diseases and intensive care physicians
2023, International Journal of Antimicrobial AgentsWhich trial do we need? Early oral antibiotic therapy for the treatment of gram-negative bloodstream infections
2023, Clinical Microbiology and Infection
- †
See Author contributions.